TScan Therapeutics, Inc. — Form 8-K
Filed August 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
TScan Therapeutics filed an 8-K on 2026-08-18 reporting termination of a material definitive agreement effective 2026-08-12 (Item 1.02). The filing provides no specifics: no counterparty name, dollar amounts, financial terms, dates of agreement execution, or business rationale are disclosed in the available document index. The actual agreement details are absent from the accessible filing materials.
Why this rating
Material agreement termination is inherently significant for a $57M biotech, but absence of disclosed terms prevents assessment. Could be routine contract wind-down or material loss—cannot judge without facts.
Extracted items
- 1.02 agreement termination
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.